AMPCASUS
DEAD

Serial Number

90860796

Owner

Celgene Corporation

Attorney

Xiomara Triana

Filing Date

Aug 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

AMPCASUS Trademark

Serial Number: 90860796

AMPCASUS is a trademark filed by Celgene Corporation on August 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Celgene Corporation (868 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

August 2, 2021

Registration Date

Not Registered

Published for Opposition

September 6, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical and biological preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders, and monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 15, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 15, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 29, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 29, 2024 EX4G
SOU EXTENSION 4 FILED
Oct 29, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 29, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 6, 2024 EXRA
SOU EXTENSION 3 GRANTED
Apr 5, 2024 EX3G
SOU EXTENSION 3 FILED
Apr 5, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 5, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 14, 2023 EXRA
SOU EXTENSION 2 GRANTED
Oct 12, 2023 EX2G
SOU EXTENSION 2 FILED
Oct 12, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 12, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 26, 2023 EXRA
SOU EXTENSION 1 GRANTED
Apr 24, 2023 EX1G
SOU EXTENSION 1 FILED
Apr 24, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 24, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 1, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 6, 2022 NPUB
PUBLISHED FOR OPPOSITION
Sep 6, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 17, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 30, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 29, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 29, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 29, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 29, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 18, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 18, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 27, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 27, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 27, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 20, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2021 NWOS
NEW APPLICATION ENTERED
Aug 5, 2021 NWAP